loading
Precedente Chiudi:
$9.51
Aprire:
$9.45
Volume 24 ore:
25,102
Relative Volume:
0.27
Capitalizzazione di mercato:
$72.13M
Reddito:
$123.24M
Utile/perdita netta:
$136.00K
Rapporto P/E:
-475.50
EPS:
-0.02
Flusso di cassa netto:
$-148.99M
1 W Prestazione:
+22.88%
1M Prestazione:
+23.85%
6M Prestazione:
-48.60%
1 anno Prestazione:
-36.75%
Intervallo 1D:
Value
$9.15
$9.555
Intervallo di 1 settimana:
Value
$7.17
$9.78
Portata 52W:
Value
$6.53
$30.60

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name
Nome
Seres Therapeutics Inc
Name
Telefono
617 945 9626
Name
Indirizzo
200 SIDNEY STREET, CAMBRIDGE, MA
Name
Dipendente
103
Name
Cinguettio
@SeresTX
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
MCRB's Discussions on Twitter

Confronta MCRB con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
MCRB
Seres Therapeutics Inc
9.51 72.13M 123.24M 136.00K -148.99M -0.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.50 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
519.20 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
319.85 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
561.36 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
260.06 28.51B 3.81B -644.79M -669.77M -6.24

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-08 Downgrade Chardan Capital Markets Buy → Neutral
2024-10-24 Downgrade JP Morgan Neutral → Underweight
2023-06-26 Ripresa Oppenheimer Outperform
2023-04-21 Iniziato JP Morgan Neutral
2021-07-23 Downgrade Goldman Neutral → Sell
2021-05-18 Ripresa Goldman Neutral
2021-03-05 Aggiornamento Chardan Capital Markets Neutral → Buy
2020-09-18 Downgrade Chardan Capital Markets Buy → Neutral
2020-08-18 Iniziato Piper Sandler Overweight
2020-08-11 Reiterato H.C. Wainwright Buy
2020-08-11 Aggiornamento Jefferies Hold → Buy
2019-04-30 Iniziato Jefferies Hold
2018-10-22 Iniziato Chardan Capital Markets Buy
2017-10-13 Iniziato Oppenheimer Outperform
2017-08-04 Reiterato H.C. Wainwright Buy
2017-02-01 Reiterato FBR & Co. Outperform
2016-08-12 Reiterato FBR Capital Outperform
2016-08-01 Downgrade BofA/Merrill Buy → Neutral
2016-08-01 Reiterato H.C. Wainwright Buy
2016-07-29 Ripresa H.C. Wainwright Buy
2016-03-30 Iniziato FBR Capital Outperform
2016-03-03 Iniziato Guggenheim Buy
2016-01-25 Iniziato H.C. Wainwright Buy
2015-10-22 Aggiornamento BofA/Merrill Neutral → Buy
2015-07-22 Iniziato Canaccord Genuity Buy
2015-07-21 Iniziato Goldman Neutral
2015-07-21 Iniziato Leerink Partners Outperform
Mostra tutto

Seres Therapeutics Inc Borsa (MCRB) Ultime notizie

pulisher
Jun 12, 2025

FMR LLC Reduces Stake in Seres Therapeutics Inc: A Strategic Rea - GuruFocus

Jun 12, 2025
pulisher
Jun 02, 2025

Denodo University Challenge Now Open: Data and AI for Real-World Impact - GlobeNewswire Inc.

Jun 02, 2025
pulisher
Jun 01, 2025

5 Best Microbiome Companies (June 2025) - Securities.io

Jun 01, 2025
pulisher
May 28, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of “Reduce” by Brokerages - Defense World

May 28, 2025
pulisher
May 27, 2025

Seres Therapeutics reports promising biomarker data By Investing.com - Investing.com South Africa

May 27, 2025
pulisher
May 27, 2025

Seres Therapeutics (MCRB) to Present New Biomarker Data at ASCO 2025 | MCRB Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Seres Therapeutics reports promising biomarker data - Investing.com

May 27, 2025
pulisher
May 27, 2025

Seres Therapeutics to Present New Biomarker Data from SER-155 Phase 1b Study at 2025 ASCO Annual Meeting - Nasdaq

May 27, 2025
pulisher
May 27, 2025

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting - The Manila Times

May 27, 2025
pulisher
May 27, 2025

Breakthrough: Seres Therapy Cuts Deadly Infection Risk by 77% in Cancer Transplant Patients, ASCO Data Shows - Stock Titan

May 27, 2025
pulisher
May 23, 2025

Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

May 23, 2025
pulisher
May 17, 2025

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - Defense World

May 17, 2025
pulisher
May 16, 2025

Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade - NewsBreak: Local News & Alerts

May 16, 2025
pulisher
May 12, 2025

Human Microbiome Market Forecast: Growth Trends, Key Players & - openPR.com

May 12, 2025
pulisher
May 11, 2025

Seres Therapeutics’ (MCRB) “Neutral” Rating Reiterated at Chardan Capital - Defense World

May 11, 2025
pulisher
May 09, 2025

StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold - Defense World

May 09, 2025
pulisher
May 08, 2025

Seres Therapeutics Shares Fall After Downgrade From Chardan - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript - Insider Monkey

May 08, 2025
pulisher
May 08, 2025

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga

May 08, 2025
pulisher
May 08, 2025

Chardan Downgrades Seres Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $25 - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

MCRB: Seres Therapeutics' Price Target Raised by Chardan Capital | MCRB Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Chardan cuts Seres Therapeutics stock rating to neutral - Investing.com

May 08, 2025
pulisher
May 08, 2025

Seres Therapeutics: Q1 Earnings Snapshot - Norwalk Hour

May 08, 2025
pulisher
May 08, 2025

Seres Therapeutics Reports Positive Q1 2025 Results - TipRanks

May 08, 2025
pulisher
May 07, 2025

Seres Therapeutics’ Positive Earnings Call: Progress and Challenges - TipRanks

May 07, 2025
pulisher
May 07, 2025

Transcript : Seres Therapeutics, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

Earnings call transcript: Seres Therapeutics Q1 2025 sees net income boost - Investing.com Nigeria

May 07, 2025
pulisher
May 07, 2025

Seres Therapeutics, Inc. SEC 10-Q Report - TradingView

May 07, 2025
pulisher
May 07, 2025

Seres Therapeutics Advances SER-155 Program with FDA Submission - TipRanks

May 07, 2025
pulisher
May 07, 2025

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times

May 07, 2025
pulisher
May 07, 2025

Seres Therapeutics (MCRB) Targets Advancement of SER-155 in Clinical Development | MCRB Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Seres Therapeutics Inc Qtrly EPS $3.76 - marketscreener.com

May 07, 2025
pulisher
May 06, 2025

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 - The Globe and Mail

May 06, 2025
pulisher
May 06, 2025

Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) PT at $80.00 - Defense World

May 06, 2025
pulisher
May 05, 2025

Seres Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 01, 2025

Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com - Defense World

May 01, 2025
pulisher
Apr 29, 2025

Seres Therapeutics Reveals Game-Changing Biomarkers for IBD Treatment, Seeks Development Partners - Stock Titan

Apr 29, 2025
pulisher
Apr 29, 2025

Seres Therapeutics (MCRB) to Unveil New Findings at 2025 Digesti - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases - The Manila Times

Apr 29, 2025
pulisher
Apr 28, 2025

Investor’s Delight: Seres Therapeutics Inc (MCRB) Closes Weak at 0.70, Down -2.90 - DWinneX

Apr 28, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 25, 2025

Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - Defense World

Apr 25, 2025

Seres Therapeutics Inc Azioni (MCRB) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Seres Therapeutics Inc Azioni (MCRB) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Shaff Eric D.
CEO and President
May 16 '25
Sale
7.28
220
1,602
10,102
DesRosier Thomas
Chief Legal Officer and EVP
May 15 '25
Sale
7.28
79
575
7,287
Henn Matthew R
See Remarks
May 16 '25
Sale
7.28
77
561
4,383
Young Teresa L.
See Remarks
Feb 18 '25
Sale
0.81
3,338
2,704
97,536
Henn Matthew R.
See Remarks
Feb 18 '25
Sale
0.81
3,953
3,204
84,443
Shaff Eric D.
CEO and President
Feb 18 '25
Sale
0.81
12,726
10,314
192,039
DesRosier Thomas
Chief Legal Officer and EVP
Feb 18 '25
Sale
0.81
4,300
3,485
142,456
von Moltke Lisa
See Remarks
Feb 18 '25
Sale
0.81
4,416
3,579
39,875
DesRosier Thomas
Chief Legal Officer and EVP
Nov 18 '24
Sale
0.54
878
475
135,192
von Moltke Lisa
See Remarks
Nov 18 '24
Sale
0.54
977
528
32,415
$20.61
price up icon 0.78%
$36.03
price up icon 0.39%
$21.65
price up icon 1.34%
$105.24
price up icon 0.02%
$104.98
price up icon 0.19%
biotechnology ONC
$264.93
price down icon 1.26%
Capitalizzazione:     |  Volume (24 ore):